The U.S. FDA issued a warning letter to Philips (PHG) regarding its medical device facilities in Washington, Pennsylvania, and the Netherlands. “During these inspections, FDA investigators determined that Philips Ultrasound and Philips Medical Systems Nederland B.V. manufacture a variety of medical devices, such as the EPIQ Elite Ultrasound system, manufactured at Bothell, Ultrasound Transducers manufactured at Reedsville, and the IntelliSpace Cardiovascular and the eCareManager, manufactured at Nederland. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act, these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHG:
- Philips introduces cath lab integration that synchronizes pre-operative CT data
- Philips announces 5,000th installation of Philips Zenition
- Philips price target raised to EUR 23 from EUR 22 at Citi
- Philips entered into national partnership in USA with Optum Healthcare
- Philips to extend two forward contracts for 2M incentive plan shares
